19404-18-3

Basic information

• Product Name: 5-CHLORO-3-METHYLBENZO[B]THIOPHENE
• Synonyms: 5-CHLORO-3-METHYLTHIANAPHTHENE;5-CHLORO-3-METHYLBENZO[B]THIOPHENE;5-Chloro-3-Methylbenzothiophene97%;5-Chloro-3-methylbenzobüthiophene, 97%;5-Chloro-3-methylbenzo[b]thiophene ,97%;5-CHLORO-3-METHYLBEN;5-Chloro-3-Methylbenzothiophene;5-chloro-3-Methyl-1-benzothiophene
• CAS NO: 19404-18-3
• Molecular Formula: C₉H₇ClS
• Molecular Weight: 182.67
• Product Categories: Thiophene&Benzothiophene;Heterocycle-oher series
• Mol File: 19404-18-3.mol
• Article Data: 17

Chemical Properties

• Melting Point: 33 °C
• Boiling Point: 87 °C
• Flash Point: 163.1°C
• Appearance: /
• Density: 1.293g/cm³
• Vapor Pressure: 0.00641mmHg at 25°C
• Refractive Index: 1.66
• Storage Temp.: 2-8°C
• Solubility: soluble in Methanol
• CAS DataBase Reference: 5-CHLORO-3-METHYLBENZO[B]THIOPHENE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-3-METHYLBENZO[B]THIOPHENE(19404-18-3)
• EPA Substance Registry System: 5-CHLORO-3-METHYLBENZO[B]THIOPHENE(19404-18-3)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 26-37/39
• Hazardous Substances Data: 19404-18-3(Hazardous Substances Data)

Usage

Chemical Properties

White to light yellow solid

InChI:InChI=1/C9H7ClS/c1-6-5-11-9-3-2-7(10)4-8(6)9/h2-5H,1H3

Upstream product

• 25784-83-2 (p-chlorophenylthio)acetone 
• 106-54-7 p-Chlorothiophenol 
• 71-43-2 benzene 
• 78-95-5 chloroacetone 

Downstream Products

• 212078-62-1 3-chloro-1-(5-chloro-3-methylbenzo[b]thiophen-2-yl)propan-1-one 
• 406235-96-9 methyl 4-(3-methyl-1-benzothien-5-yl)benzoate 
• 463976-34-3 6-(5-chloro-3-methylbenzothiophene-2-sulfonyl)-3-methoxypyridazine 
• 16296-68-7 5-chloro-benzo[b]thiophene-3-carbaldehyde 
• 22105-89-1 5-(iso-propyl)-3-methyl-1-benzothiophene 
• 19404-20-7 3-methylbenzo[b]thiophen-5-amine 

Relevant articles and documents

TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.

Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands

A series of N-(2-(5-fluoro-2-(4-fluorophenylthio)benzo[b]thiophen-3-yl) ethyl)acylamides was synthesized and evaluated for binding affinity and intrinsic activity at melatonin receptors. The affinity of each compound for the melatonin receptors was determined by binding studies on cloned human MT 1 and MT2 receptors expressed in CHO cells. Agonist and antagonist potency was measured on the [35S]GTPγS binding assay for the most interesting compounds. The new derivatives 8-14 showed modest to high selectivity (between 4 and 220) for MT2 receptors. The most selective compound, N-(2-(5-fluoro-2-(4-fluorophenylthio)benzo[b]thiophen-3-yl) ethyl)but-3-enamide (14), an MT2 ligand with affinity for the MT 2 receptor similar to that of melatonin and a 220-fold preference over MT1 receptors, acts as a partial agonist. In addition, N-(2-(5-fluoro-2-(4-fluorophenylthio)benzo[b]thiophen-3-yl)ethyl)propionamide (9), a nanomolar MT2 ligand with a good selectivity ratio (MT 1/MT2 = 51) shows antagonist activity on both melatonin receptors.

Use of alpha-1C specific compounds to treat benign prostatic hyperplasia

PCT No. PCT/US93/10950 Sec. 371 Date Apr. 1, 1997 Sec. 102(e) Date Apr. 1, 1997 PCT Filed Nov. 12, 1993 PCT Pub. No. WO94/10989 PCT Pub. Date May 26, 1994A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human alpha 1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human alpha 1A adrenergic receptor, a human alpha 1B adrenergic receptor, and a human histamine H1 receptor, and, binds to a human alpha 2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such alpha 1C adrenergic receptor. Compounds meeting these criteria are provided.